The Women’s Tennis Association has enacted one of the most far-reaching eligibility rule changes in the sport’s modern history, requiring every player on tour to undergo genetic s3x testing as a condition of eligibility to compete.
Sources state that the policy, which took effect July 1, 2026, represents a decisive philosophical departure from the WTA’s previous approach to gender inclusion and appears to make the tour the first independent professional women’s sports league to mandate such screening across its entire membership.
At the center of the new rules is a test for the SRY gene, typically administered through a cheek swab. The SRY gene is a small section of DNA usually found on the Y chromosome that triggers fetal development of testes rather than ovaries. If a player’s test comes back negative for the gene’s presence, she is cleared to compete, and because genetic makeup does not change across a lifetime, the test only needs to be administered once.
If the result is positive, the player faces further medical assessment and can only continue competing if she can prove she has Complete Androgen Insensitivity Syndrome or another disorder of s3x development that means she has never experienced the physiological effects of male puberty, including the hormonal surge that occurs in early infancy. The testing program is being administered by Colorado-based Phuel Sports Science.
The policy document states its purpose plainly: “to preserve the integrity of women’s professional tennis and maintain fair competition conditions for all players participating in WTA Tournaments.”
This marks a sharp turn from the WTA’s 2024 eligibility framework, which used welcoming language and established a pathway for transgender players to compete upon meeting testosterone thresholds. That earlier policy was “intended to facilitate the participation in WTA Tournaments of transgender players and players with differences of s3x development who have a female or non-binary gender identity, in a safe and supportive environment that is free from harassment and abuse.”
Under that framework, a transgender woman was required to maintain blood testosterone below 2.5 nmol/L for at least 24 months before competing, and neither legal recognition of gender identity nor surgical changes were required. The 2026 policy replaces that entire framework with the SRY gene test, with no testosterone-based eligibility pathway remaining.
The new policy has not been formally added to the publicly accessible WTA rulebook. The 2026 rulebook contains only a reference to a “WTA Women’s Eligibility Policy” available upon request through WTA Legal.
Among the more notable details in the document is a change in legal jurisdiction. While the 2024 policy was governed by New York law, the 2026 version anchors legal authority in Florida.
The document reads: “This policy is governed by the laws of the state of Florida, excluding Florida conflict of law principles. Notwithstanding anything to the contrary in the WTA Rulebook or WTA By-Laws, the validity, legality and/or enforceability of this policy may only be challenged before a federal or state court located in Saint Petersburg, Florida, which is the WTA’s principal place of business.”
Players must sign an acknowledgment form outlining the consequences of noncompliance. The language makes clear that a player who refuses testing or competes while knowing she is ineligible could face disciplinary measures, and that such proceedings may not remain private.
As the form states: “I acknowledge that if I fail to undergo SRY Screening as requested by the WTA or compete in a WTA Tournament in which I, to my knowledge, am ineligible to compete under this Eligibility Policy, the WTA may take disciplinary action against me… I further acknowledge and agree that such action may result in (among other things) a specified period of ineligibility to participate in WTA Tournaments, which may lead to the reason for my ineligibility becoming public knowledge or being the subject of public speculation.”
The WTA has built in a provision for professional counseling, covered at the organization’s expense, for any player whose case requires further assessment. That acknowledgment reflects a well-documented historical pattern: genetic screening of female athletes has previously caused real harm to women with rare chromosomal variations who had no prior reason to question their identity.
Research published in the journal Medicine and Science in Sports and Exercise in 2002 found that “genuine s3x-impostors have not been uncovered by laboratory-based genetic testing; however, gender verification procedures have resulted in substantial harm to a number of women athletes born with relatively rare genetic abnormalities.”
The new policy arrives at a moment when no transgender women are known to be active at any level of professional women’s tennis. In fact, only one transgender woman has ever competed in women’s professional tennis: Renée Richards, who won a court case in the 1970s granting her the right to compete and went on to reach the women’s doubles final at the 1977 U.S. Open. She did not disrupt the competitive balance of the sport, and no transgender players followed her into the professional ranks.
The WTA’s decision places it alongside a broader recent movement across international sport. The International Olympic Committee adopted a similar SRY gene screening approach earlier this year, describing it as “protection of the female category.”
Those developments followed policy changes by the U.S. Olympic Committee and the NCAA, each linked to pressure from the Trump administration’s executive order on the composition of women’s sports. Notably, however, the WTA’s adoption of comparable standards is a choice rather than a requirement. Unlike World Tennis, formerly the International Tennis Federation, the WTA has no affiliation with the IOC and no obligation to align its rules with the Olympic body’s framework.
The cultural debate over transgender athletes in women’s sports has grown far louder than the actual numbers suggest is warranted. Among the most prominent voices has been 18-time major champion Martina Navratilova, who has made the issue a defining focus of her public presence in recent years. N
When WTA world No. 1 Aryna Sabalenka was asked about competing against transgender women during a December appearance on Piers Morgan Uncensored, she described it as a “tricky question” before adding: “I have nothing against them, but I feel like they still got a huge advantage over the women and I think it’s not fair on women to face, basically, biological men.”
Such comments from active players remain rare. The subject surfaces infrequently in press conferences or post-match interviews, and most players on tour have opted not to engage with it publicly.
The WTA updated its official website to publish the new policy following the initial news reports, with player screening set to begin later in 2026 alongside a player engagement program and confidentiality protections.
